Literature DB >> 21498391

Of timing and surrogates: a way forward for cancer chemoprevention.

Patricia A Thompson1, Eugene W Gerner.   

Abstract

Cancer chemoprevention strategies are not widely implemented in clinical practice. Targeting biomarkers in patients with elevated risk of developing cancer by means of short-term administration of certain agents may be a strategy to minimize toxicities while maintaining efficacy in clinical trials that can be completed in years rather than decades. ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21498391      PMCID： PMC3574815          DOI： 10.1158/1078-0432.CCR-11-0643

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention.

Authors:  Bernard Levin
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

2.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

3.  Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.

Authors:  C Mel Wilcox; Jeroan Allison; Keith Benzuly; Marie Borum; Byron Cryer; Tilo Grosser; Richard Hunt; Uri Ladabaum; Angel Lanas; Harold Paulus; Carol Regueiro; Robert S Sandler; Lee Simon
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-31       Impact factor: 11.382

4.  Cancer chemoprevention--the cardiovascular model.

Authors:  Robert Temple
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

Review 5.  Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

Authors:  Sharlene Gill; Frank A Sinicrope
Journal:  Semin Oncol       Date:  2005-02       Impact factor: 4.929

6.  National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.

Authors:  Carolanne Dai; Randall S Stafford; G Caleb Alexander
Journal:  Arch Intern Med       Date:  2005-01-24

7.  Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Authors:  Tetsuji Takayama; Hiroyuki Nagashima; Masahiro Maeda; Shuichi Nojiri; Michiaki Hirayama; Yoichiro Nakano; Yasuo Takahashi; Yasushi Sato; Hitoshi Sekikawa; Mitsuru Mori; Tomoko Sonoda; Tetsuo Kimura; Junji Kato; Yoshiro Niitsu
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

8.  Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Authors:  Nancy L Cho; Mark Redston; Ann G Zauber; Adelaide M Carothers; Jason Hornick; Andrew Wilton; Stephen Sontag; Norman Nishioka; Francis M Giardiello; John R Saltzman; Chris Gostout; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2008-04-14

Review 9.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.

Authors:  Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

10.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245
  10 in total
  3 in total

1.  Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.

Authors:  Swati Chandra; Ariel C Nymeyer; Photini Faith Rice; Eugene W Gerner; Jennifer K Barton
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

Review 2.  Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.

Authors:  Nathaniel S Rial; Jason A Zell; Alfred M Cohen; Eugene W Gerner
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-08       Impact factor: 3.869

3.  Cellular diamine levels in cancer chemoprevention: modulation by ibuprofen and membrane plasmalogens.

Authors:  Paul L Wood; M Amin Khan; Tara Smith; Dayan B Goodenowe
Journal:  Lipids Health Dis       Date:  2011-11-16       Impact factor: 3.876
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.